TRPM2 and myeloid leukemia: ROS, key determinants of DNA damage, are significantly increased in neuroblastoma25,32 and myeloid leukemia cells3 with TRPM2 deletion treated with doxorubicin, compared to control, from both increased ROS production and reduced antioxidant defenses3,25,32.